Abstract Peroxisome proliferator-activated receptor gamma (PPAR ) is a multifunctional transcription factor that regulates adipogenesis, immunity and inXammation. Our laboratory previously demonstrated that PPAR ligands induce apoptosis in malignant B cells. While malignant B lineage cells such as B cell lymphoma express PPAR , its physiological function remains unknown. Herein, we demonstrate that silencing PPAR expression by RNAi in human Burkitt's type B lymphoma cells increased basal and mitogen-induced proliferation and survival, which was accompanied by enhanced NF-B activity and increased expression of Bcl-2. These cells also had increased survival upon exposure to PPAR ligands and exhibited a less diVerentiated phenotype. In contrast, PPAR overexpression in B lymphoma cells inhibited cell growth and decreased their proliferative response to mitogenic stimuli. These cells were also more sensitive to PPAR -ligand induced growth arrest and displayed a more diVerentiated phenotype. Collectively, these Wndings support a regulatory role for PPAR in the proliferation, survival and diVerentiation of malignant B cells. These Wndings further suggest the potential of PPAR as a therapeutic target for B cell malignancy.
Introduction
Burkitt's lymphoma (BL) is an aggressive non-Hodgkin B cell lymphoma usually diagnosed in children and young adults. In the United States and Western Europe, it constitutes about 1-2% of all adult lymphomas and 30-50% of pediatric lymphomas [14, 28] . BL has also been associated with Epstein-Barr virus (EBV) latent infection, which results in a lymphoproliferative phenotype and increased resistance to apoptosis [21] . Intensive chemotherapeutic regimens have greatly increase prognosis, but can have signiWcant toxicity, including treatment-related deaths [14] . New courses of therapy are aimed at minimizing toxicity without compromising outcome, and include monoclonal antibody (Rituximab) and steroid therapies. Recent molecular evidence of the role of transcription factors in BL is yielding promise as therapeutic targets [41] .
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of transcription factors that regulate lipid metabolism and adipose diVerentiation [6] . There are three known PPAR isoforms: PPAR , PPAR / and PPAR . The human PPAR gene is located on chromosome 3, band 3p25 [3] . This gene gives rise to three mRNA isoforms (PPAR 1, 2 and 3) through alternate promoter usage and splicing [18] . Both PPAR 1 and PPAR 3 mRNA translate into PPAR 1 protein and PPAR 2 mRNA gives rise the PPAR 2 isoform that contains 28 extra amino acids [18] . All PPAR isoforms heterodimerize with members of the retinoid X receptor (RXR) subfamily of nuclear hormone receptors. These complexes then bind to the peroxisome proliferator response element (PPRE) in the promoter regions of target genes. PPAR is activated by natural ligands such as 15-deoxy- 12, 14 prostaglandin J 2 (15d-PGJ 2 ) and by certain polyunsaturated fatty acids. PPAR can also be activated by synthetic ligands such as the thiazolidinediones (TZDs) class of anti-diabetic drugs. PPAR also has anti-proliferative, anti-inXammatory and pro-diVerentiating properties in immune cells [20] . Importantly, PPAR regulates B lymphocyte function. B lymphocytes from PPAR -haploinsuYcient mice exhibit increased proliferation and survival [54] . Our laboratory (and others) have demonstrated that both normal and malignant B lymphocytes express PPAR and that exposure to certain PPAR ligands inhibits B cell proliferation and induces apoptosis [42, 43, 49] . Some studies have shown that PPAR ligands induce diVerentiation of malignant cells [11, 39] . Moreover, PPAR expression increases during diVerentiation of monocytes to macrophages [40] . In hematological malignancies, PPAR ligands can induce monocytic diVerentiation in myeloid leukemia cells and help sensitize malignant cells to the prodiVerentiation eVects of all trans-retinoic acid [16, 24, 34, 35, 57] . These studies support the concept that PPAR is an important transcription factor in B cells and serves as a pro-diVerentiation factor for malignant cells.
The ability of PPAR to alter B cell proliferation and apoptosis may relate to its ability to repress other transcription factors, such as nuclear factor kappa-B (NF-B) [20] . NF-B controls B cell proliferation and survival [19, 30] and is constitutively active in several human cancers, including B cell lymphomas [44, 51] . Moreover, EBV activates NF-B in the process of B cell transformation to malignancy [27] . Straus et al. [56] reported that the natural PPAR ligand 15d-PGJ 2 inhibits multiple steps in the NF-B signaling pathway. PPAR may also regulate NF-B by obstructing its transcription [9] . A recent report by Pascual et al. demonstrated that PPAR -ligand-dependent sumoylation of PPAR leads to the recruitment of PPAR to the repressor complexes on the promoter regions of genes regulated by NF-B, ultimately suppressing NF-B driven gene expression [45] .
Thus, PPAR may control B cell lymphoma proliferation and survival through alterations in NF-B activity. We hypothesized that the level of PPAR plays an important role in B lymphoma cell survival. We speculated that high levels of PPAR would inhibit proliferation/survival and induce diVerentiation, while low PPAR levels would enhance B lymphoma survival and enhance their undiVerentiated phenotype. Herein, we investigated the eVects of PPAR expression on B cell lymphoma proliferation, survival and diVerentiation.
Materials and methods

Reagents and antibodies
Ciglitazone was purchased from Biomol (Plymouth Meeting, PA). CDDO was synthesized by Dr. T. Honda and kindly provided by Dr. Michael Sporn (Dartmouth College, Hanover, NH) [25] . [3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide] MTT, DMSO and anti-Flag M2 monoclonal antibody peroxidase conjugate were from Sigma (St Louis, MO). The anti-PAX-5 was purchased from Millipore (Billerica, MA). The anti-BLIMP-1 was purchased from Novus Biologicals (Littleton, CO). The rabbit anti-human PPAR antibody was purchased from Biomol. Anti-Bcl-2 (sc-7382) and anti-p65 (sc-372) antibodies were purchased from Santa Cruz (Santa Cruz, CA). Total actin (CP-01) antibody was from Oncogene (Cambridge, MA).
Construction of lentiviral vectors
The lentiviral vector encoding the short hairpin RNA (shRNA) against PPAR transcripts (nucleotides 1095-1113) was constructed using the oligonucleotide sequence 5ЈGTTTGAGTTTGCTGTGAAG3Ј, as described by Katayama et al. [31] . The two complementary oligonucleotides were cloned downstream of the human RNA polymerase III U6 promoter and then subcloned into the FG12 lentiviral vector (gift of Dr. David Baltimore), as described earlier [48] (see also Fig. 1a) .
The LV-PPAR 1-WT and the LV-empty vector were produced as described earlier [17] .
Lentiviral vector production
Human embryonic kidney 293FT cells (Invitrogen, Carlsbad, CA) were grown to 50-70% conXuency in Dulbecco's modiWed Eagle's medium (GIBCO, Carlsbad, CA) supplemented with 10% fetal bovine serum in T-175 Xasks. Subsequently, the VSVG pseudotyped HIV vector was generated by co-transfecting with 5 g of envelope vector (pCMV-VSVG), 14 g of transfer vector and 14 g of packaging vector pCMV-89.2, using Lipofectamine LTX (Invitrogen, Carlsbad, CA). Cells were split into two T-175 Xasks 6 h post-transfection. Supernatants were collected 48 and 72 h post-transfection. Virus was harvested by ultracentrifugation at 50,000£g for 2 h at 4°C using a Beckman SW 28 rotor. The concentrated virus stocks were titered on 293FT cells based on GFP expression. 
Lentiviral infections and cell sorting
Ramos and Raji B lymphoma cells were plated at a density of 1 £ 10 6 cells/well in a 12 well plate and infected with the diVerent lentiviral vectors at MOIs of 1-5 in the presence of 6 g/ml of polybrene. Twenty-four hours post-infection, the growth media was replaced. Lentiviral transduced cells were identiWed on the basis of the GFP expression. GFP-positive cells were sorted by Xow cytometry using a FACSAria (BD Bioscience, San Jose, CA).
ImmunoXuorescence
Ramos B lymphoma cells infected with the lentiviral constructs were incubated with mouse anti-human CD19-APC (BD Biosciences), anti-human CD38-PE (BD Biosciences), anti-human CD20-PE (BD Biosciences) or with anti-human CD40-biotin (Axxora/Ancell, Bayport, MN) in cold PBS with sodium azide (0.02%) and BSA (0.3%) for 20 min at 20°C. For CD40 surface staining, cells were washed and incubated with secondary APC-conjugated streptavidin (Caltag, Burlingame, CA).
Electrophoretic mobility shift assay (EMSA) for NF-B Gel shift assay of nuclear extracts from uninfected, LVcontrol and LV-PPAR -siRNA infected Ramos cells was performed as described [49] .
PPAR activity assay
Nuclear extracts from LV-Empty infected or LV-PPAR -WT infected Ramos cells were collected using a nuclear extract kit (Active Motif, Carlsbad CA). To determine PPAR activity, a TransAM PPAR activity assay kit was used (Active Motif, Carlsbad CA) as described [1] . 5 cells per well) were plated in a 96-well Xat bottom microtiter plate. MTT was performed to assess cell viability. The tetrazolium salt MTT is taken up by viable cells and reduced to a formazan residue by functional mitochondria of living cells [4] . Cells were treated with increasing concentrations of the PPAR ligand CDDO and 10 l per well of a 5 mg/ml of MTT (in 1£ PBS) was added for the last 4 h of incubation. After incubation, the plate was centrifuged, the media removed and DMSO was added to each well to dissolve the precipitate. The plate was read at 510 nm on a Benchmark microplate reader (BioRad, Hercules, CA).
For the proliferation assay, cells were cultured as described above, and were left untreated or were treated with CD40L [29] , 10 g/ml of rabbit anti-human F(abЈ) 2 anti-IgM Ab (Jackson ImmunoResearch Laboratories) and 1/1,000 dilution of Pansorbin (Staphylococcus aureus Cowen I strain; Sigma-Aldrich) or diVerent combinations of these mitogens; 1 Ci/well of 3 H-thymidine was added for the last 18 h of culture. The cells were harvested onto a 96-well Wlter plate and the 3 H-thymidine incorporation was detected as counts per minute (cpm) using a Topcount Luminometer (PerkinElmer, Boston, MA).
Cell cycle analysis
Cell cycle analysis of human BL cells was performed using the APC Bromodeoxyuridine (BrdU) Flow kit (BD Pharmingen, San Diego, CA) according to the manufacturer's instructions. In the set of experiments using ciglitazone, cells were treated with ciglitazone (5 M) for 48 h. Cells were then pulsed for 30 min with 10 nM BrdU and stained the APC-BrdU Xow kit.
Western blots
Whole cell extracts were collected using ELB buVer [50 mM HEPES (pH 7), 250 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 10 mM NaF, 0.1 mM Na 3 VO 4 , 50 M ZnCl 2 , supplemented with 0.1 mM PMSF, 1 mM DTT and a mixture of protease and phosphatase inhibitors] and total protein was quantiWed using bicinchoninic acid protein assay (BCA assay kit) (Pierce, Rockford, IL). A total of 25 g protein was electrophoresed on 8-16% Precise™ protein gels (Pierce, Rockford, IL) and transferred to a polyvinylidene Xuoride (PVDF) membrane (Millopore, Billerica, MA). The membranes were analyzed for immunoreactivity with the indicated primary antibody, washed and then incubated with an appropriate horse radish peroxidase-conjugated secondary antibody. The membranes were visualized by chemiluminescence using an ECL kit (Pierce, Rockford, IL).
Statistical analysis
Results are expressed as the mean § standard deviation. Two-tailed Student t test was performed and P < 0.05 were considered signiWcant. All experiments were repeated at least three times.
Results
Construction of a lentiviral-based vector for delivery of PPAR siRNA
Our laboratory previously demonstrated that both normal and malignant B cells express PPAR and that certain PPAR ligands induce apoptosis [42, 43, 49, 50] . To determine the physiological role of PPAR expression in certain human B cell lymphomas, we used a lentivirus-mediated shRNA expression system to knockdown PPAR expression in Burkitt's B lymphoma cells. To construct the siRNA expression cassette, a target sequence of siRNA for PPAR was selected to knockdown both PPAR 1 and PPAR 2 [31] . The 19 bp PPAR target sequence was cloned downstream of the human RNA polymerase III U6 promoter and then subcloned into the FG12 lentiviral vector, which also expresses GFP under the Ubiquitin C (UbiC) promoter (Fig. 1a) [48] . First, to determine whether the siRNA sequence eVectively targets human PPAR mRNA, the DNA plasmid vector containing the siRNA sequence was tested in human embryonic kidney (HEK) 293 cells. HEK 293 cells were mock transfected (Fig. 1b,  pcDNA 3 .1, lane 1) or were co-transfected with a FLAG-tagged PPAR -wild type vector (Fig. 1b , Flag-PPAR , lanes 2-6) and with an empty DNA vector (Fig. 1b, pcDNA 3.1, lane 2) , or increasing DNA concentrations of the parental empty vector (FG12-empty, lanes 3 and 4), or increasing concentrations of the PPAR siRNA expression vector (FG12-siRNA-PPAR , lanes 5 and 6). Exogenous PPAR expression was tested using an anti-FLAG antibody and endogenous PPAR expression was tested using an anti-PPAR antibody. Both exogenous and endogenous PPAR protein levels were dramatically reduced in HEK293 cells that co-expressed the PPARFlag vector and the FG12-siRNA-PPAR vector (Fig. 1b , compare lane 2 with lanes 5 and 6), but not in cells co-transfected with PPAR -Flag and the FG12-empty vector (Fig. 1b, compare lane 2 with 3 and 4) . This indicates that the siRNA sequence against PPAR was successful at knocking down PPAR expression. Next, the pseudotyped lentiviral vectors were generated as described in Materials and methods and designated LV-control and LV-PPAR -siRNA. Both vectors also express GFP. Ramos B lymphoma cells were infected at an MOI of 5. Approximately 30% of the Ramos B cells were transduced as determined by GFP expression (Fig. 1c, left panel) . These GFP-positive cells were sorted and 5 days post-sorting, the cells were analyzed by Xow cytometry to determine the purity. More than 98% of the cells were GFP-positive (Fig. 1c, right panel) . Western blot analysis conWrmed that LV-PPAR -siRNA infected Ramos B cells have dramatically reduced levels of PPAR protein (Fig. 1d) .
Reduction of PPAR expression in Ramos B lymphoma cells results in enhanced proliferation and reduced sensitivity to PPAR agonist-induced cell death
We Wrst investigated whether PPAR plays a role in B lymphoma proliferation. Proliferation was measured by 3 H-thymidine incorporation. Control (LV-Control) and PPAR -knockdown (LV-PPAR -siRNA) Ramos cells were left untreated or were stimulated with Pansorbin (Wxed S. aureus), human CD40L, anti-IgM, CD40L + anti-IgM or CD40L + Pansorbin for 24 h. Basal proliferation (Fig. 2a, untreated) was signiWcantly increased following lentiviral delivery of PPAR -siRNA. There was also a signiWcant increase in the proliferative response to mitogenic stimuli in PPAR -knockdown cells in comparison to control Ramos cells (Fig. 2a) . This indicates that the presence of PPAR dampens B lymphoma cell proliferation.
We next evaluated whether PPAR -knockdown Ramos B cells would have increased survival upon exposure to the synthetic PPAR ligand, CDDO (Fig. 2b) . Control and PPAR -knockdown Ramos cells were exposed to increasing concentrations of CDDO for 24hr and viability measured by MTT. PPAR -knockdown Ramos cells have increased survival when exposed to lethal doses of PPARligand CDDO. This increase in survival was also conWrmed using 7-AAD staining (data not shown). PPAR -knockdown cells also had better survival following serum depravation compared to control cells (data not shown). Taken together, these results indicate that PPAR regulates cell proliferation and survival in B lymphoma cells.
PPAR knockdown B lymphoma cells display a less diVerentiated phenotype
To explore the eVect of PPAR on B cell diVerentiation and activation, we examined the eVect of PPAR knockdown on several important B cell markers. During B cell diVerentiation, CD38 expression increases while CD19 and CD20 levels are downregulated [2, 7] . Therefore, we compared the levels of CD20, CD19 and CD38 of control Ramos cells versus PPAR -knockdown Ramos cells by Xow cytometry. The surface expression of CD38 in PPAR -siRNA Ramos cells was slightly lower than PPAR -expressing Ramos cells (LV-control) (Fig. 3a, panel 3) . Conversely, surface expression of CD20 and CD19 in PPAR -siRNA Ramos cells was increased (Fig. 3a, panels 1 and 2) . These results suggest that PPAR participates in B cell diVerentiation.
We also investigated the eVects of PPAR knockdown on the expression of two transcription factors crucial for B cell diVerentiation: Paired box protein 5 (PAX-5) and B lymphocyte-induced maturation protein 1 (BLIMP-1) [33] . During B cell diVerentiation PAX-5 levels are downregulated and/or inactivated, while BLIMP-1 is upregulated [33] . We observed a marked reduction in BLIMP-1 expression in PPAR -knockdown cells compared to control cells, while the levels of PAX-5 remain relatively unchanged (Fig. 3b) . Together, these results, in conjunction with the changes seen in B cell diVerentiation surface markers (Fig. 3a) , suggest that the reduction of BLIMP-1 expression is the result of transcriptional regulation by PPAR and correlates with a less diVerentiated phenotype.
PPAR knockdown Ramos B lymphoma cells have enhanced NF-B activity and express higher levels of the NF-B-dependent pro-survival gene Bcl-2 NF-B is an important transcription factor for B cell proliferation and survival [22] . Because previous studies have demonstrated the direct eVects of PPAR on NF-B [32, 46] , we investigated whether PPAR expression aVected NF-B. First, the expression of the NF-B subunit p65 was investigated in PPAR -knockdown Ramos cells versus uninfected and control Ramos cells. Nuclear and cytoplasmic extracts were collected from uninfected, control and siRNA-PPAR transduced Ramos cells and western blot analysis for the NF-B p65 subunit was performed. An accumulation of p65 occurred in the nucleus (tthreefold induction compared to controls), with a concomitant decrease in the cytoplasm (tWvefold reduction compared to controls), of PPAR -knockdown Ramos cells in comparison to uninfected and control cells (Fig. 4a) . Next, an EMSA was performed on nuclear extracts (described in "Materials and methods") from uninfected, LV-control and LV-PPAR -siRNA infected Ramos cells to measure NF-B DNA binding activity. Figure 4b shows that PPARknockdown Ramos cells have increased NF-B DNA binding activity in comparison to uninfected and control cells. Bcl-2 is an anti-apoptotic protein that has an important role in normal and malignant B cell proliferation and survival [52] . Bcl-2 is also a key target gene of NF-B. Therefore, we investigated the levels of Bcl-2 in PPAR -siRNA Ramos cells, uninfected and control Ramos cells. PPARknockdown Ramos cells had ttenfold higher Bcl-2 levels compared to uninfected or control Ramos cells (Fig. 4c) . These Wndings support the idea that PPAR regulates NF-B activation.
Design of a lentiviral-based vector for PPAR 1 overexpression in human B lymphoma cells
To further determine the physiological role of PPAR in human B cell lymphoma, overexpression studies were performed using a lentiviral vector we constructed for PPAR gene delivery. The lentiviral vector contains a Flag-tagged PPAR 1 cDNA under the control of the CMV promoter and Copecod GFP (CopGFP) under the EF1-promoter. As a control, the backbone lentiviral vector that only expresses CopGFP was used (Fig. 5a ). Ramos cells were infected at an MOI of 5 and GFP-positive Ramos cells were sorted by Xow cytometry. Interestingly, we observed a decrease in GFP expression over time after sorting. We hypothesized that selective pressure was responsible for decreasing the levels of both PPAR and GFP (Fig. 5b) . For these reasons, cells were only cultured for a maximum of 1 month after sorting, at which time we evaluated the eVects of PPAR overexpression. The presence of exogenous PPAR expression was determined by western blot using an anti-FLAG antibody. We found that cells stably transduced with LV-PPAR , but not LV-empty nor uninfected cells expressed the Flag-tagged PPAR protein (Fig. 5c) . To test whether the overexpressed PPAR was capable of binding DNA, an ELISA-based assay to quantify the binding of PPAR to its promoter response element was used. Cells overexpressing PPAR had a twofold increase in PPAR activity compared to LV-empty infected cells (Fig. 5d ). These results demonstrate that the increased levels of PPAR were able to bind DNA and activate transcription.
Ramos B lymphoma cells transduced with LV-PPAR have a decreased proliferative response
We next determined the eVects of PPAR overexpression on B lymphoma cell proliferation using 3 H-thymidine incorporation. Both basal proliferation, as well as stimulated proliferative responses was tested. Ramos B lymphoma cells stably transduced with LV-empty or LV-PPAR were untreated or were stimulated with CD40L, anti-IgM, Pansorbin and combination of CD40L + antiIgM or CD40L + Pansorbin for 24 h. LV-empty expressing cells were able to respond to stimuli, as seen by an increase in 3 H-thymidine incorporation (Fig. 6a) . However, LV-PPAR transduced cells poorly responded to mitogenic stimuli. The robust proliferative response to CD40L (with or without anti-IgM or Pansorbin) was dramatically reduced following PPAR overexpression (Fig. 6a) . Since PPAR overexpression inhibited B lymphoma cell proliferation, we next assessed cell cycle kinetics using BrdU and 7-AAD double staining. LV-PPAR transduced cells had a decrease in the percentage of cells in the S-phase of the cell cycle when compared to those of LV-empty infected control cells (47% in LV-empty cells vs. 39% in LV-PPAR cells) (Fig. 6b) . These results conWrm that PPAR overexpression inhibited basal cell growth of B lymphoma cells. To determine whether PPAR overexpression had the same eVect on another BL cell line, EBV + Raji B lymphoma cells were infected at an MOI of 5. GFP-positive cells were then sorted and tested for basal proliferation using BrdU and 7-AAD staining. LV-PPAR overexpressing Raji B lymphoma cells also showed a decrease in the percentage of cells in S-phase, while the fraction of cells with G0/G1 and G2/M DNA content was increased in comparison to LVempty cells (Fig. 6c) . We next investigated whether these cells were more sensitive to PPAR ligand-mediated growth inhibition. To test this, we treated LV-empty and LV-PPAR Raji cells with a sublethal dose of the PPAR ligand, Ciglitazone (5 M). Ciglitazone treatment had a minimal eVect on proliferation of LV-empty infected cells Fig. 4 PPAR knockdown Ramos B lymphoma cells have enhanced NF-B activity and express higher levels of the NF-B-dependent prosurvival gene Bcl-2. a Nuclear and cytoplasmic extracts from uninfected, LV-control and LV-PPAR -siRNA transduced Ramos cells were collected and NF-B p65 levels analyzed by western blot. Total actin was used as a loading control. Graph shows representative densitometry. b Nuclear extracts were incubated with a radiolabeled DNA binding sequence for NF-B and a gel shift assay was performed. c Bcl-2 protein expression was analyzed by western blot in whole cell lysates from uninfected, LV-control and LV-PPAR -siRNA transduced Ramos B cells. Graph shows representative densitometry (compare LV-empty and LV-empty + Cig). However, ciglitazone treatment resulted in further growth inhibition when PPAR was overexpressed (LV-PPAR ), as seen by an even lower number of cells in the S-phase of the cycle (Fig. 6c , compare LV-PPAR and LV-PPAR + Cig). These Wndings indicate that PPAR negatively regulates cell proliferation by decreasing the number of cells entering S-phase and further enhanced their susceptibility to PPAR -ligand induced cell cycle arrest.
PPAR -overexpressing B lymphoma cells display a more diVerentiated phenotype
Since reduced PPAR expression in B lymphoma cells resulted in a less diVerentiated phenotype (Fig. 3) , we next explored whether PPAR overexpression had an eVect on B cell diVerentiation markers (CD20, CD19 and CD38) and activation marker (CD40) expression (Fig. 7a) . Surface expression of CD38 was not changed and CD19 expression were then sorted on the basis of GFP expression. GFP expression was monitored over time (one day and one week after sorting) to determine purity and the stability of gene expression c Exogenous PPAR 1 expression was evaluated by western blotting using an anti-FLAG antibody. After sorting, the FLAG-PPAR protein was detected in the cells infected with LV-PPAR , but not in the LV-empty infected cells. -Tubulin levels were assayed to normalize protein loading. d Nuclear extracts from Ramos cells stably transduced with either LV-empty or LV-PPAR were collected and transactivation of PPAR was analyzed by ELISA using TransAm ® technology (*P < 0.05) was slightly reduced by PPAR overexpression. Additionally, surface expression of CD20 and CD40 were dramatically reduced in PPAR -overexpressing Ramos cells (Fig. 7a) . These results suggest a role for PPAR in B cell diVerentiation and activation. To conWrm that PPAR regulates diVerentiation of Ramos cells, we next examined the eVects of PPAR overexpression on PAX-5 and BLIMP-1. BLIMP-1 expression was upregulated in LV-PPAR -infected cells in comparison to LV-empty infected cells. In contrast, the levels of PAX-5 were downregulated in these cells (Fig. 7b) . Therefore, we propose that PPAR promotes diVerentiation of germinal center (GC) B cell-derived cells toward plasma cells. 
Discussion
Burkitt's lymphoma is an aggressive form of non-Hodgkin lymphoma, and it is the most common childhood cancer in Central Africa [14] . Although the survival rates have increased, new innovative therapies are needed. PPAR and PPAR ligands have emerged as a new molecular target to treat cancer. Data from our laboratory (and others) have demonstrated that ligand-initiated activation of PPAR inhibits growth and induces apoptosis in B cell malignancies [34, 42, 43, 47, 49, 50] . Further, PPAR expression correlates with patient prognosis in certain cancers [53, 58] . In the present study, we demonstrated that alterations of PPAR expression levels in the GC B cell-derived cells Ramos and Raji aVect cell proliferation, survival and diVerentiation. Interestingly, a decrease in PPAR expression was associated with an increase in B lymphoma cell proliferation and survival, both basally and after mitogenic stimuli (Fig. 2a) . Moreover, PPAR -knockdown malignant B cells survive better when exposed to increasing doses of CDDO in comparison to PPAR -expressing cells (Fig. 2b) . These data, in conjunction with our recently published results [42, 43, 50] , further conWrm that part of the cytotoxic eVects of PPAR ligands are mediated directly through PPAR .
Nuclear Factor-kappa B is an important transcription factor for B cell development and survival. Activation of the NF-B pathway induces expression of anti-apoptotic proteins, such as the Bcl-2 family members [22] . The antiinXammatory eVects of PPAR have been linked to the inhibition of NF-B [46] . Studies performed in PPAR haploinsuYcient mice indicate that PPAR is important in controlling B cell proliferation and survival. These mice exhibit enhanced B cell proliferation after LPS stimulation and increased NF-B activity in comparison to their wild type counterparts [54] . Here, we showed that PPAR knockdown human B lymphoma cells have increased NF-B activity and increased levels of the anti-apoptotic protein Bcl-2, which supports the mouse studies. PPAR has also been proposed to have pro-diVerentiating properties [5, 16, 34] . During normal B cell diVerentiation, the levels of CD20 and CD19 are downregulated, whereas the levels of CD38 are upregulated. We observed that upon PPAR downregulation, there was a reduction of CD38 surface expression and an increase of CD20 and CD19 expression, indicative of a less diVerentiated phenotype. These Wndings demonstrate that the expression of PPAR , as well as its activity, is necessary to control B cell lymphoma proliferation, survival and diVerentiation. Although we did not observed changes in CD38 expression upon PPAR overexpression, we observed a slight decrease in CD19 surface expression and a considerable decrease in CD20 expression on PPAR -overexpressing B lymphoma cells, which correlates with a more diVerentiated phenotype. Therefore, we speculate that PPAR overexpression would improve the outcome of patients with B cell lymphoma, since a more diVerentiated phenotype correlates with a better prognosis [15] .
Studies performed in thyroid carcinoma cells demonstrated that PPAR overexpression resulted in an induction of cell cycle arrest and cell death [37] . In concordance with these studies, when we overexpressed PPAR in BL cells, and recently in multiple myeloma [17] , we found that PPAR overexpression inhibited both basal and stimulated proliferation in B lymphoma cells. Interestingly, we observed a decrease in GFP expression in lymphoma cells over time. These results might explain a direct eVect of PPAR overexpression on GFP transcription, or a deleterious eVect of PPAR that confers growth disadvantage to PPAR overexpressing cells. We hypothesize that over time, selective pressure was responsible for decreasing the levels of both PPAR and GFP. In addition, we observed a decrease of CD40 expression in cells overexpressing PPAR . Previous studies have shown that CD40 ligation can rescue BL from B cell receptor crosslinking-induced cell death [26] . Therefore, we speculate that reduced levels Fig. 7 Ramos B lymphoma cells overexpressing PPAR showed a more diVerentiated phenotype. a Ramos B lymphoma cells stably transduced with LV-Empty or LV-PPAR were analyzed for the expression of CD20, CD19, CD38 and CD40. Cells that overexpress PPAR showed a slight decrease on CD19 expression and a dramatic decrease on CD20 and CD40, but no changes in CD38 expression. b LV-empty and LV-PPAR infected cells were lysed and expression of PAX-5 and BLIMP-1 were analyzed by western blot as indicated. Total actin was used to normalize protein loading of surface expression of CD40 would render the lymphoma cells less responsive to CD40 ligand stimulation and subsequently contribute to their reduced cell growth and survival.
We propose that PPAR regulates B lymphoma cell diVerentiation. PAX-5 is inactivated by an unknown stimulus and is one of the Wrst steps needed for plasma cell diVerentiation, while BLIMP-1 is upregulated. BLIMP-1 functions as an important regulator of plasma cell diVerentiation by inhibiting proliferation through inhibition of c-myc, an important factor for cell proliferation [36, 55] . BLIMP-1 also represses PAX-5, which is crucial during B cell diVerentiation [55] . In addition to the changes on surface expression of B cell diVerentiation markers (Fig. 3a and Fig. 7a) , there was also a reduction of BLIMP-1 in the PPAR knockdown cells and an upregulation with PPAR overexpression. While the expression of PAX-5 was relatively unchanged upon PPAR knockdown, the levels of PAX-5 were downregulated in cells overexpressing PPAR . Collectively, these Wndings suggest that PPAR may regulate B cell diVerentiation via direct or indirect regulation of key transcription factors, such as BLIMP-1 and PAX-5 and may contribute, at least in part, to the inhibitory eVects of PPAR on proliferation and cell cycle progression in B cell lymphomas.
Collectively, our Wndings support PPAR as a potential new target to control malignant B lymphoma proliferation, survival and diVerentiation. Therapeutic eVorts to alter PPAR levels in malignant B cells may demonstrate synergistic cytotoxicity when used in conjugation with PPAR ligands. One mechanism to selectively target malignant B cells in vivo would be to use lentiviral vectors that have a B cell lymphoma-speciWc promoter, thereby allowing therapeutic gene expression only in malignant B cells. A new generation of lentiviral vectors known as self-inactivating vectors (SIN) allows restriction or silencing of gene expression regulated by the viral promoter [10] . This feature makes possible the use of an internal promoter (e.g. B cell lymphoma-speciWc) to drive the gene of interest. In fact, this method has recently been used to introduce therapeutic genes in mammalian cells [8, 12, 13, 38] . For example, in multiple myeloma, the use of a minimal immunoglobulin promoter as well as the kappa light chain intronic and 3Ј enhancers to drive the gene of interest was able to selectively transduce myeloma cells [12] . Therefore, using a cell or tissue-speciWc promoter and/or enhancer element could target a speciWc cell population. One possible candidate would be the promoter or enhancer regions of c-myc, which is highly expressed in BL [23] .
